Monday, June 11, 2012 8:47:46 AM
1 - BIEL's management has not done this before and all that means, compared to a J&J or a Pfizer with huge scientific horsepower and communication and documentation skills;
2 - Money and all that means; and
3 - BIEL's product line had had FDA stumped as to classification for some time.
The combination of these reasons is not grounds for going postal. Please relax, otherwise some may infer you are only trying to generate negativity because you are short a ton of shares at .0020. I don't believe that is the case, I think you are simply venting your frustrations at the passage of time, which we will never get back. So? Let's move forward.
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM